Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 4

The treatment of chronic hepatitis B: Focus on adefovir-like antivirals

Authors Tillmann HL

Published 8 August 2008 Volume 2008:4(4) Pages 797—802


Hans Ludger Tillmann

Medizinische Klinik und Poliklinik II, Universität Leipzig, Germany

Abstract: Several options for the treatment of hepatitis B have been licensed in the last years: interferon, pegylated interferon, lamivudine, adefovir, entecavir, and telbivudine. In addition tenofovir has been licensed in the EU and is expected to be licensed in the USA in 2008. The antivirals can be divided into “lamivudine-like” and “adefovir-like”, which clinically differ in their capacity to induce “YMDD” mutants, which are the hallmark of lamivudine resistance. The differing resistance profile makes them good combination partners, even in the absence of synergy in antiviral potency.

Keywords: adefovir, tenofovir, pradefovir, almefovir, antiviral therapy, hepatitis B

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:


Rapidis A, Sarlis N, Lefebvre J-L, et al

Therapeutics and Clinical Risk Management 2008, 4:1381-1381

Published Date: 5 December 2008

Methotrexate-induced cutaneous ulceration in patients with erythrodermic mycosis fungoides

Debra L Breneman, Timothy J Storer, John C Breneman, Diya F Mutasim

Therapeutics and Clinical Risk Management 2008, 4:1135-1141

Published Date: 10 October 2008

Beclomethasone/formoterol fixed combination for the management of asthma: patient considerations

Gabriele Nicolini, Nicola Scichilone, Andrea Bizzi, Alberto Papi, Leonardo M Fabbri

Therapeutics and Clinical Risk Management 2008, 4:855-864

Published Date: 10 October 2008

Early ischemic CT changes before thrombolysis: The influence of age and diabetes mellitus

Lars Thomassen, Ulrike Waje-Andreassen, Halvor Naess

Therapeutics and Clinical Risk Management 2008, 4:699-703

Published Date: 8 August 2008

Treating refractory leukemias in childhood, role of clofarabine

Theresa M Harned, Paul S Gaynon

Therapeutics and Clinical Risk Management 2008, 4:327-336

Published Date: 11 April 2008

Pharmacological causes of hyperprolactinemia

Daria La Torre, Alberto Falorni

Therapeutics and Clinical Risk Management 2007, 3:929-951

Published Date: 15 November 2007

Bortezomib (Velcade™) in the treatment of multiple myeloma

Antonia Field-Smith, Gareth J Morgan, Faith E Davies

Therapeutics and Clinical Risk Management 2006, 2:271-279

Published Date: 15 September 2006